Ultime notizie per Genenta Science (NASDAQ:GNTA) Azioni

Genenta Science

Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.

Genenta Science S.p.A. - American Depositary Shares

Genenta Science SPA

JFBR

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

LUXH

JFBRW

LUXHP

"The days of retail being a fringe player are over," said Eric Krueger, CEO of GTN Americas at <a href="https://benzinga.swoogo.com/fintech-awards/6073689">Benzinga Fintech Deal Day</a>, during a panel called "Bridging Divides: Connecting Wall Street with Main Street.&#8221;
The panel, moderated by Brandis DeSimone, head of data sales at Nasdaq, brought together voices from Public.com, Alpaca, TradeZero and GTN to explore innovation, education and the global rise of retail trading.
See Also:<a href="https://www.benzinga.com/news/events/24/11/42072183/will-ai-become-an-assistant-or-a-master-experts-beg-to-differ-at-benzinga-fintech-conference"> Will AI Become An Assistant Or A Master? Experts Beg To Differ At Benzinga Fintech Conference</a> Reflecting on his early days at Merrill Lynch, Krueger described how trading has evolved from $100 commissions to instant, no-cost trades on a mobile app. "That friction is gone, and it's made retail a major force in the market."
But the increasing presence of retail investors raised questions about their readiness for sophisticated markets. 
On one side, Samuel Nofzinger, head of Brokerage and Crypto at Public.com, argued that learning through mistakes is essential. "We can't be too paternalistic," he said. "Guardrails are important, but you have to let people fail. That's how they grow from chasing meme stocks to building diversified portfolios."
Yoshi Yokokawa, CEO of Alpaca, offered a cautious counterpoint, warning about the dangers of pushing risk too far. "We've seen what happens when innovation outpaces responsibility, like during the crypto boom and bust," he said. 
Yokokawa, who worked at Lehman Brothers during the 2008 financial crisis, stressed that fintech companies have a duty to balance access with protection. "We have to ask: how much risk should we be introducing to the average investor?"
<h1 class="wp-block-heading">Innovation vs. Responsibility</h1>
One recurring theme was how to simplify complex financial products without oversimplifying their risks. Nofzinger pointed to Public's approach to fixed-income products as an example. 
"Bonds are complicated, but we've repackaged them into something retail investors understand: a yield-focused account," he said. The result was striking — on launch day, Public handled 8% of all U.S. bond trades.
"Offering a new product is great, but making it digestible is where the real work happens," Krueger noted. He warned against overwhelming retail users with overly complex choices. "Retail investors don't wake up thinking, ‘Let me buy some bonds.' They think, ‘Where can I get the best yield?' Simplifying that process is key."
Yokokawa agreed but remained wary of the long-term implications. "When you chase yield, you're pushing the limits," he said. "That's how boom-and-bust cycles happen. We have to remember that retail isn't just numbers — it's people's savings, their futures."
<h1 class="wp-block-heading">Striking A Balance: Education and Risk</h1>
Panelists debated the best approach to educating retail investors without stifling their autonomy. Nofzinger talked about meeting users where they are, including platforms such as TikTok and Meta Platform&#8217;s Instagram. "If you're not there, you're invisible to this generation of investors," he said.
Meanwhile, Daniel Pipitone, co-founder and CEO of TradeZero, focused on working with unbiased educators to teach strategies and risk management. He echoed Nofzinger's belief that mistakes are part of the process. "You can't control what people do, and they need room to learn. But platforms need to provide tools that help guide them responsibly."
Krueger added a different perspective, calling for education to be embedded directly into trading platforms. "It's not enough to have a help section buried in a menu. If someone is overtrading after a loss, we need to deliver advice right then and there," he said. "It's about personalization, not one-size-fits-all solutions."
<h1 class="wp-block-heading">Main Street Is Everywhere</h1>
Retail's expansion is not just a U.S. story — it's a global one. Pipitone described how demand for U.S. equities is booming abroad. "Main Street has expanded beyond borders," he said. "People everywhere want to trade Tesla or Nvidia because these brands are part of their lives."
Krueger noted that 90% of trading volumes for GTN's international partners are in U.S. markets, driven by the consistent outperformance of American stocks. 
Yet scaling globally isn't easy. "Serving smaller markets means you need incredibly low costs," Yokokawa explained. "That only works if you internalize every part of your operations, from technology to customer acquisition."
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/events/24/11/42073346/exclusive-retail-investors-are-taking-on-more-risk-and-finding-success-is-crypto-acting-as-a-gateway-trade">EXCLUSIVE: Retail Investors Are Taking On More Risk And Finding Success — Is Crypto Acting As A &#8216;Gateway Trade?&#8217;</a></li>
</ul>
Photo: Shutterstock

Fintech news covering the emerging Financial Technology services sector

Fintech

Retail Sales

Events

Exclusives

Personal Finance

EXCLUSIVE: Wall Street Meets Main Street — Fintech Experts Weigh In On Retail's Rise

Robert Mitchnick, head of digital assets at BlackRock, told a panel at the Benzinga <a href="https://www.benzinga.com/digital-assets">Future of Digital Assets </a>conference on Nov. 19 that options volume on the iShares Bitcoin Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>) breached the 1 billion <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42058823/blackrocks-spot-bitcoin-etf-to-open-for-options-trading-heres-why-it-could-be-a-big-deal-for-bitcoin">mark on Tuesday. </a>
"Things happen fast here," Mitchnick said. 
The Details: Nasdaq began listing options on BlackRock's spot Bitcoin ETF on Tuesday with 73,000 contracts traded in the first 90 minutes, ranking IBIT options among the top 20 most active non-index options. 
BlackRock's IBIT is currently the only spot Bitcoin ETF listed on Nasdaq, but competitors listed on the New York Stock Exchange (NYSE) and Cboe Global Markets are expected to launch similar options trading in the coming days.
Bloomberg senior ETF analyst Eric Balchunas noted that the volume was almost entirely calls, indicating a strong bullish sentiment in Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>). 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">A few hundred million so far in options volume on <a href="https://twitter.com/search?q=%24IBIT&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$IBIT</a> (a ton for Day One).. here&#39;s a rank of the contracts by volume, it&#39;s almost all calls. Seems very bullish, esp the Dec20th C100, which is basically betting price of btc will double in the next month. <a href="https://t.co/R6HB7OMUla">pic.twitter.com/R6HB7OMUla</a>
&mdash; Eric Balchunas (@EricBalchunas) <a href="https://twitter.com/EricBalchunas/status/1858916477384225005?ref_src=twsrc%5Etfw">November 19, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42071163/blackrock-spot-bitcoin-etf-options-on-nasdaq-rack-up-9-figure-trading-volume-in-first-few-hours-seems-very-bullish-says-analyst">derivatives market </a>for traditional assets can often grow to be up to 20 times the size of the underlying asset&#8217;s market cap. If Bitcoin derivatives follow a similar trajectory, the listing of IBIT options could significantly expand the reach and functionality of Bitcoin-linked financial products.
"There's a ton of work to do to flesh out the investor opportunity and uptake around what we have," Mitchnick said. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/41949068/bitcoin-could-reach-1-million-by-2037-economist-says-buy-of-a-lifetime-opportunity">Bitcoin Could Reach $1 Million By 2037, Economist Says: &#8216;Buy Of A Lifetime&#8217; Opportunity</a></li>
</ul>
Photo: John Dave from Pixabay

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

Specialty ETFs

Options

Movers

ETFs

$BTC

IBIT

BlackRock's Head Of Digital Assets Says IBIT Spot Bitcoin ETF Options Blow Past 1 Billion In Trading Volume

Congressman Matt Gaetz (R-Fla.) resigned from office after he was announced as President-elect Donald Trump's pick<a href="https://www.benzinga.com/news/legal/24/11/41956594/matt-gaetz-is-trumps-attorney-general-pick-would-be-top-cop-is-under-house-ethics-investigation"> for attorney general.</a>
While Gaetz has not been formally nominated for the White House role, his resignation could keep an investigation into his actions from being publicly released.
What Happened: Prior to<a href="https://www.benzinga.com/news/24/11/42024613/lawyer-ethics-committee-witness-says-she-saw-ag-nominee-gaetz-having-sex-with-a-minor"> resigning from Congress</a>, Gaetz was under investigation by the House Ethics Committee for allegations of sexual misconduct, drug use and more.
With Gaetz no longer a member of Congress, the Ethics Committee has no jurisdiction over him, but their decision of whether to release their findings publicly remains one of the biggest topics for Congress this week.
The Ethics Committee, which is evenly split between Democrats and Republicans, is expected to meet Wednesday to determine their next step in whether to release the report or not, the Wall Street Journal <a href="https://www.wsj.com/politics/policy/senators-want-details-on-sexual-misconduct-allegations-as-gaetz-seeks-fair-shake-7a1bfad7?mod=hp_lead_pos1">reported</a>.
The report would likely include the committee's findings into allegations that Gaetz had sexual relations with a 17-year-old minor. The former minor and another woman both said Gaetz paid them for sex, according to comments from their lawyer on Monday.
Gaetz denied allegations of having sex with a minor, sex trafficking or paying for sex previously.
Speaker of the House Mike Johnson (R-La.) said this week it would be a bad precedent if the committee releases the report with Gaetz no longer a member of Congress.
See Also: <a href="https://www.benzinga.com/politics/24/11/42077496/donald-trumps-personnel-picks-new-poll-finds-elon-musk-with-highest-approval-by-voters-matt-gaetz-with-highest-disapproval">Donald Trump&#8217;s Personnel Picks: New Poll Finds Elon Musk With Highest Approval By Voters, Matt Gaetz With Highest Disapproval</a>
Some members of Congress, including members of the Republican party, want to see the results of the committee ahead of a potential vote for Gaetz to be a member of Trump's cabinet.
"I'm saying to the people that want any cabinet person to get through — not just Gaetz — but it's going to be a lot faster if you give us all the information that we want," Sen. Chuck Grassley (R-Iowa) said.
The Ethics Committee previously planned to release their findings last week before Gaetz surprising resignation.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent111924">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: While The Republicans will have a majority of 53-47 when the new Congress term begins in January, four Republicans voting against any pick could see them fail to be approved through, assuming all Democrats vote against the candidate.
On Tuesday it was reported that an "unknown and unauthorized third party" gained access to depositions from witnesses in the Gaetz investigation, as <a href="https://www.cbsnews.com/news/matt-gaetz-depositions-leak-investigations/">reported </a>by CBS News.
The reported leak, which could include testimony from the minor who allegedly had sex with Gaetz, could put into question whether more details from the case will be released publicly, even if Congress doesn't do so.
On <a href="https://polymarket.com/event/who-will-be-trumps-attorney-general?tid=1732054162608">Polymarket</a>, the odds of Gaetz being approved as attorney general currently stand at 38%, up from <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42014985/matt-gaetz-to-be-confirmed-as-attorney-general-in-a-trump-administration-not-so-fast-polymarket-traders-say">28% four days ago. </a>The odds had previously hovered between 25% and 30%, before growing in recent days.
Gaetz has the best odds of any name listed in the Polymarket attorney general prediction market. On Polymarket, users can deposit funds using USDC (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>) via the Polygon (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/matic/usd">MATIC</a>) network, or directly from a crypto account with Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>).
Each betting market sees the winning option pay out at $1. Like the 2024 election markets, the odds of potential cabinet members are becoming hot betting markets on Polymarket.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/42036132/trump-wants-matt-gaetz-confirmed-100-so-does-the-cannabis-industry">Trump Wants Matt Gaetz Confirmed &#8216;100%,&#8217; So Does The Cannabis Industry</a></li>
</ul>
Photo: Shutterstock

Government

Politics

Legal

$ETH

$MATIC

$USDC

USDC

Trump's Attorney General Pick Matt Gaetz Resigned From Congress, Ethics Committee To Decide If Report Will Be Released

President-elect Donald J. Trump <a href="https://www.benzinga.com/general/health-care/24/11/42077057/trump-picks-dr-oz-as-centers-for-medicare-and-medicaid-services-administrator">announced on Tuesday afternoon</a> that he will nominate TV personality Dr. Mehmet Oz to serve as the administrator of the Centers for <a href="https://www.benzinga.com/etfs/24/11/42044642/trump-appears-frustrated-as-elon-musk-chimes-in-on-treasury-secretary-adds-more-names-to-a-list-of-potential-picks" target="_blank" rel="noreferrer noopener">Medicare and Medicaid Services (CMS)</a>. The appointment is among a string of TV hosts — mostly from Fox News — to be chosen to join Trump's cabinet.
In a statement, Trump said the celebrity TV host will "work closely with Robert F. Kennedy Jr. to take on the illness industrial complex."
Though a household name due to his long-running &#8220;The Dr. Oz Show" (2009-2022), Oz got into politics when he <a href="https://www.benzinga.com/markets/cannabis/22/06/27558526/dr-oz-to-face-john-fetterman-in-unprecedented-unpredictable-pa-senate-race-and-cannabis-is-on-th">unsuccessfully ran for Senate</a> against now Sen. John Fetterman (D-Penn.) in 2022, during which time the good doctor seemed to forge an alliance with Trump.
At the time, Scientific American&nbsp;<a href="https://www.scientificamerican.com/article/dr-oz-shouldnt-be-a-senator-or-a-doctor/" target="_blank" rel="noreferrer noopener">wrote </a>Dr. Oz should not&nbsp;be a senator or a doctor, noting that his misinformation had already tarnished medicine and would do much worse in the halls of Congress.&nbsp;"Dr. Oz&nbsp;has long pushed misleading, science-free and unproven alternative therapies such as homeopathy, as well as fad diets, detoxes and cleanses."
<h1 class="wp-block-heading">Donald Trump Begs To Differ</h1>
News outlets are quick to<a href="https://www.axios.com/2024/11/19/trump-dr-oz-cms-cabinet"> point out</a> that Dr. Oz has no experience running a large government body like the CMS but that seems to not matter because, according to the President-elect.
&#8220;There may be no Physician more qualified and capable than Dr. Oz to Make America Healthy Again,&#8221; Trump said in a statement, referring to the words of <a href="https://www.benzinga.com/topic/robert-f-kennedy-jr">Robert Kennedy Jr</a>. who will, if confirmed run the Dept. of Health and Human Services.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/42036132/trump-wants-matt-gaetz-confirmed-100-so-does-the-cannabis-industry">Trump Wants Matt Gaetz Confirmed &#8216;100%,&#8217; So Does The Cannabis Industry</a>
<h1 class="wp-block-heading">Dr. Oz On Cannabis</h1>
The multimillionaire TV host initially called cannabis a &#8220;mixed bag for easing pain.&#8221; But a recent discussion with&nbsp;Michael Roizen,&nbsp;M.D., of the Wellness Institute at the Cleveland Clinic, Dr. <a href="https://www.benzinga.com/markets/cannabis/24/08/40492959/trump-endorsed-dr-oz-on-medical-marijuana-and-pain-give-it-a-try">Oz said</a>, &#8220;Our advice: If your physician recommends it to manage pain, especially if you&#8217;re 65 and older, give it a try.&#8221;
While Dr. Oz cautions against cannabis consumption for recreational purposes, he said he believes marijuana for pain represents a "safer solution than, for example, narcotics in many cases."
During his Senate race, Dr. Oz often criticized Fetterman&#8217;s support for cannabis legalization though several years earlier he himself <a href="https://www.marijuanamoment.net/dr-oz-claims-dea-and-fda-blame-each-other-for-keeping-marijuana-illegal/">referred to cannabis</a>&nbsp;as "one of the most underused tools in America" and that the U.S. should&nbsp;"completely change our policy on marijuana."
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/42069004/how-trumps-election-could-revolutionize-cannabis-and-cryptocurrency-ceo-says">How Trump&#8217;s Election Could Revolutionize Cannabis And Cryptocurrency, CEO Says</a></li>
</ul>

Cannabis

Health Care

Trump Picks Dr. Oz, Who Says Seniors Should Give Medical Marijuana A Try, To Lead Centers For Medicare And Medicaid Services

AZEK Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZEK#NYSE">AZEK</a>) sees FY2025 sales of $1.510 billion-1.540 billion vs $1.43 billion estimate.

Guidance

AZEK

AZEK Co Sees FY2025 Sales $1.510B-1.540B vs $1.43B Est

Kore Group Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KORE#NYSE">KORE</a>) raises FY2024 sales outlook from $275.00 million-285.00 million to $280.00 million-285.00 million.

KORE

Kore Group Holdings Raises FY2024 Sales Guidance from $275.00M-285.00M to $280.00M-285.00M

Varex Imaging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VREX#NASDAQ">VREX</a>) is looking for Q1 Adj EPS of $(0.05)-0.10 vs $0.04 analyst estimate. sees sales of $195.000 million-215.000 million vs $189.43 million estimate.

VREX

Varex Imaging Sees Q1 Adj EPS $(0.05)-0.10 vs $0.04 Est; Sees Sales $195.000M-215.000M vs $189.43M Est

Keysight Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEYS#NYSE">KEYS</a>) is looking for Q1 Adj EPS of $1.65-1.71 vs $1.57 analyst estimate. sees sales of $1.265 billion-1.285 billion vs $1.26 billion estimate.

KEYS

Keysight Techs Sees Q1 Adj EPS $1.65-1.71 vs $1.57 Est; Sees Sales $1.265B-1.285B vs $1.26B Est

Concentra Group To Replace Myers Industries In S&P SmallCap 600 Effective Prior To Opening Of Trading On November 27

AZTA

Azenta To Replace Envestnet In S&P SmallCap 600 Effective Prior To The Opening Of Trading On November 25

FLEX

Flex To Replace Azenta In S&P MidCap 400

Donald Trump has announced several picks for potential nominees for his White House administration since winning the <a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election">2024 presidential election.</a>
While the picks still have to be nominated and approved in many cases, voters were recently asked to share whether they approve of or disapprove of his current selections.
What Happened: Trump's announced picks have generated plenty of discussion on social media and across the political spectrum with the announced picks of Matt Gaetz <a href="https://www.benzinga.com/news/legal/24/11/41956594/matt-gaetz-is-trumps-attorney-general-pick-would-be-top-cop-is-under-house-ethics-investigation">as attorney general</a> and Robert F. Kennedy Jr. leading the Health and Human Services generating the most buzz.
A new Morning Consult <a href="https://pro.morningconsult.com/analysis/trump-transition-nominees-approval">poll </a>asked voters how they think Trump is doing with his transition.
The poll found that 54% of voters approve of Trump's handling of his transition since winning the 2024 election, with 38% disapproving and 8% saying they don't know or had no opinion.
Split by political party, Republicans showed a higher approval rating (93%) of Trump's handling of the transition compared to Democrats (20%). Independent voters were more split with 46% approving, 40% disapproving and 14% having no opinion or saying they don't know.
Trump's 54% approval rating is only six points below the 60% approval rating President Joe Biden had four years ago from a Morning Consult poll.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent111924">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Personnel Pick Ratings: Here are the approval and disapproval ratings of recent personnel picks by Trump for his next White House term.
<ul>
<li>Mike Huckabee, U.S. Ambassador to Israel: 44% approval, 31% disapproval, 25% no opinion</li>
<li>Marco Rubio, Secretary of State: 45% approval, 34% disapproval, 21% no opinion</li>
<li>Elise Stefanik, U.S. Ambassador to the United Nations: 38% approval, 29% disapproval, 33% no opinion</li>
<li>Stephen Miller, Deputy White House Chief of Staff: 36% approval, 30% disapproval, 34% no opinion</li>
<li>Tulsi Gabbard, Director of National Intelligence: 39% approval, 33% disapproval, 29% no opinion</li>
<li>Robert F. Kennedy Jr., Health and Human Services Secretary: 44% approval, 39% disapproval, 16% no opinion</li>
<li>Elon Musk, co-leader of the Department of Government Efficiency: 45% approval, 40% disapproval, 15% no opinion</li>
<li>Vivek Ramaswamy, co-leader of the Department of Government Efficiency: 39% approval, 34% disapproval, 27% no opinion</li>
<li>Lee Zeldin, Environmental Protection Agency Administration: 34% approval, 29% disapproval, 37% no opinion</li>
<li>Pete Hegseth, Secretary of Defense: 37% approval, 32% disapproval, 31% no opinion</li>
<li>Kristi Noem, Secretary of Homeland Security: 37% approval, 33% disapproval, 30% no opinion</li>
<li>Matt Gaetz, Attorney General: 34% approval, 41% disapproval, 25% no opinion</li>
</ul>
Why It's Important: The selection of Gaetz could face the most scrutiny by members of Congress if he is formally nominated. The Republican resigned from Congress the same day Trump announced the attorney general role for him.
Gaetz was investigated by the Department of Justice for sex trafficking before it declined to charge the congressman.
The former Congressman was under investigation by the House Ethics Committee for sexual misconduct. Allegations against the Trump ally include sexual misconduct, illicit drug use, accepting improper gifts and more. Gaetz has denied the allegations.
Gaetz is the only person in the poll to receive a higher percentage of disapproval than approval.
When it comes to disapproval, Gaetz ranks first at 41% followed by Tesla CEO Elon Musk at 40%.
Musk, who has been named by Trump to lead the Department of Government Efficiency and cut government spending, also has the <a href="https://www.benzinga.com/politics/24/11/41993300/elon-musks-favorability-with-gop-voters-nearly-as-high-as-j-d-vance-how-views-of-billionaire-changed-among-political-parties">highest approval rating</a> at 45%, tied with Marco Rubio.
Musk has the lowest percent of voters saying no opinion, showing how opinionated voters are of his potential selection. Musk maintains a positive net approval rating of 45% to a disapproval rating of 40%.
Kennedy Jr. ranks among the highest for approval at 44% and for disapproval at 39%. Like Musk, Kennedy also has a low amount of voters saying they have no opinion at 16%.
Huckabee has the highest net approval rating in the poll at 13 points.
This poll was taken before Trump announced Dr. Mehmet Oz as his choice as <a href="https://www.benzinga.com/general/health-care/24/11/42077057/trump-picks-dr-oz-as-centers-for-medicare-and-medicaid-services-administrator">Centers For Medicare and Medicaid Services administrator</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/42036132/trump-wants-matt-gaetz-confirmed-100-so-does-the-cannabis-industry">Trump Wants Matt Gaetz Confirmed &#8216;100%,&#8217; So Does The Cannabis Industry</a></li>
</ul>
Photo: Musk, White House, public domain; Trump and Getz, Shutterstock

Donald Trump's Personnel Picks: New Poll Finds Elon Musk With Highest Approval By Voters, Matt Gaetz With Highest Disapproval

Telsey Advisory Group analyst Joseph Feldman maintains Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) with a Outperform and raises the price target from $92 to $100.

Price Target

Analyst Ratings

Telsey Advisory Group Maintains Outperform on Walmart, Raises Price Target to $100

ZTO Cuts 2024 Outlook For Parcel Volume From 34.73B - 35.64B To 33.7B - 33.9B Based On Current Market And Operating Conditions

KITT

Nauticus Robotics Enters Strategic Collaboration With SeaTrepid To Integrate And Test Its ToolKITT Software On Remotely Operated Vehicles

Canaccord Genuity analyst Caitlin Cronin maintains Vericel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCEL#NASDAQ">VCEL</a>) with a Buy and maintains $60 price target.

VCEL

Canaccord Genuity Maintains Buy on Vericel, Maintains $60 Price Target

Genenta Science SpA Sponsored ADR (GNTA) has released an update. Genenta Science SpA invites its shareholders to the upcoming ordinary and extraord...

Genenta Science Announces Shareholder Meeting

Genenta Science SpA Sponsored ADR (GNTA) has released an update. Genenta Science's CEO Pierluigi Paracchi has proposed a new slate of candidates fo...

Genenta Science Announces Board Restructuring

Genenta Science SpA Sponsored ADR (GNTA) has released an update. Genenta Science SpA, an Italian biotech firm, has entered into an agreement with V...

Genenta Science Announces ADS Sales Agreement

Genenta Science SpA Sponsored ADR (GNTA) has released an update. Genenta Science SpA, a biotech company based in Milan, is focused on the research,...

Genenta Science Advances Biotech Endeavors

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cingulate Inc (CING – Research Report) and Genenta...

Analysts Conflicted on These Healthcare Names: Cingulate Inc (CING) and Genenta Science SpA Sponsored ADR (GNTA)

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
One of the oldest maxims in investing is that higher risk produces greater returns. That maxim holds particularly true across penny <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks.</a> Developing therapeutics to cure diseases is a complex business model fraught with the potential to fail at many points.&nbsp;



Developmental and regulatory time frames are long, introducing multiple potential points of failure. The capital necessary for research and development is substantial. So on and so forth. The result is that many&nbsp;upstart biotech firms fail to commercialize, taking their equity down in the process.



Those firms that make it through and reach commercialization are rewarded with the spoils of success. They pay shareholders handsomely with returns that can turn a small investment into a fortune. The firms discussed below still have reasonable chances of commercialization and the potential to reward investors handsomely. Even if they don&rsquo;t ultimately reach success, they can still reward investors handsomely as they pass milestones in the development process.



<h2>FibroGen (FGEN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/pte_biotech_1600-300x169.png" alt="Medical technology network team meeting concept. Doctor hand working smart phone modern digital tablet laptop computer graphics chart interface, sun flare effect photo, PTE"><div>Source: everything possible / Shutterstock.com</div></div>FibroGen (NASDAQ:<a href="https://investorplace.com/stock-quotes/fgen-stock-quote/">FGEN</a>) continues on the path toward commercialization for multiple drugs, targeting multiple diseases. The firm&rsquo;s leading candidate drugs include Pamrevlumab, Roxadustat and several other oncology therapeutics.



Pamrevlumab is currently in Phase 3 clinical trials for the treatment of a certain form of pancreatic cancer. It is also concurrently being studied in phase 2/3&nbsp;clinical studies for metastatic pancreatic cancer. Roxadustat is a drug that induces the production of red blood cells and is approved in multiple countries for use in treating anemia in chronic kidney disease populations. A supplemental New Drug Application (sNDA) has been submitted in China for the drug. It has been accepted for review by the China Health Authority.&nbsp;



One of the more compelling aspects of FibroGen as an investment in financial performance. During the <a href="https://www.globenewswire.com/news-release/2024/05/06/2876129/33525/en/FibroGen-Reports-First-Quarter-2024-Financial-Results.html">first quarter, revenues</a> approached $56 million, up from $36 million a year earlier. The increased revenues allow the company to slash its net losses from $76.7 million to just below $32 million this quarter. Shares currently trade for $1.30 with a <a href="https://stockanalysis.com/stocks/fgen/forecast/">consensus target price of $5</a> and analyst targets ranging as high as $11.



<h2>Nuvectis Pharma (NVCT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/biopharma-1600-300x169.jpg" alt="Illustration of a biopharma company. Doctor standing in front of various medical icons."><div>Source: Billion Photos / Shutterstock</div></div>Nuvectis Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvct-stock-quote/">NVCT</a>) is another oncology-oriented biotech stock. It&rsquo;s particularly interesting as a potential investment because while it is in the pre-revenue stages, it is also highly regarded and priced higher than one might expect.



Shares currently trade for $6.21, which is quite high for a pre-revenue biotech firm. Those shares have coverage from a single analyst who expects their value to rise to $22 in the future. Investors who look at the company&rsquo;s financial statements will see that it is basically treading water. NVCT has more than $19 million in liquidity and loses roughly $4 million a quarter on R&amp;D and administrative costs.&nbsp;



The reason for optimism surrounding Nuvectis Pharma is simple: Lead candidate drug <a href="https://www.globenewswire.com/news-release/2024/05/07/2876700/0/en/Nuvectis-Pharma-Inc-Reports-First-Quarter-2024-Financial-Results-and-Business-Highlights.html">NXP800 has been granted</a> fast-track designation by the FDA in platinum-resistant ARID1a-mutated ovarian cancer. It&rsquo;s currently in Phase 1b studies and has the potential to pass through multiple milestones moving forward that, if successful, will reward investors with strong and immediate returns.



<h2>Relmada Therapeutics (RLMD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600-300x169.png" alt="OLK Stock. Modern Medical Research Laboratory: Two Scientists Wearing Face Masks use Microscope, Analyse Sample in Petri Dish, Talk. Advanced Scientific Lab for Medicine, Biotechnology. Blue Color. KZR stock. RSLS stock. Best Biotech Stocks to Buy"><div>Source: Gorodenkoff / Shutterstock.com</div></div>Relmada Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/rlmd-stock-quote/">RLMD</a>) is one of many promising late-stage biotech firms developing therapeutics to address diseases of the central nervous system. Those diseases include disorders with high unmet needs including major depressive disorder (MDD), a primary focus of the firm.



REL-1017 is one of the company&rsquo;s lead candidate drugs. The drug is in late-stage development for the treatment of MDD. It is being studied to understand the potential of the drug as a fast-acting, once-daily antidepressant treatment.&nbsp;It is currently being studied in two Phase 3 double placebo-controlled studies.



The company also acquired the rights to a psilocybin and derivatives program&nbsp;in 2021. That program has been rebranded as REL-P11 and is being studied for its efficacy in both neurogenesis and in ameliorating the effects of neurodegenerative conditions.&nbsp;



Psilocybin and other psychoactive drugs are currently a hot area of research. Although Ralmada Therapeutics is in the pre-revenue stages and shares trade for $3.04, the sole analyst with coverage believes those shares could be worth as much as $25 in the future.



<h2>Anixa Biosciences (ANIX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600-1-300x169.jpg" alt="A scientist holds a test tube while it is in a container"><div>Source: Shutterstock</div></div>Anixa Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/anix-stock-quote/">ANIX</a>) develops treatments and vaccines to address unmet needs in ovarian cancer and breast cancer. Shares currently trade for less than $3, while the single analyst with coverage believes the stock will <a href="https://www.pricetargets.com/NASDAQ/ANIX/">rise to $12 in value.</a>&nbsp;



The company very <a href="https://www.prnewswire.com/news-releases/anixa-biosciences-commences-treatment-of-fifth-patient-in-ovarian-cancer-car-t-clinical-trial-302150758.html">recently commenced treatment</a> on the 5th patient in an ovarian cancer CAR-T clinical trial. The company is enrolling patients in its first-in-human trial who were unresponsive to at least two prior therapies. Safety was confirmed in the first three-patient cohort. The company is tripling the dose in patients four and five in order to establish dosage tolerability.&nbsp;



The company also recently expanded its partnership with the Cleveland Clinic to develop cancer vaccines. That partnership aims to further the development of vaccines targeting rare and aggressive forms of breast and ovarian cancer. Anixa Biosciences will continue to be an interesting stock for investors, especially in light of strong positive news on multiple fronts.



<h2>Genenta Science (GNTA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600-min-1-300x169.jpg" alt="an image of a microscope, NEXI stock"><div>Source: Shutterstock</div></div>Let&rsquo;s begin discussing Genenta Science (NASDAQ:<a href="https://investorplace.com/stock-quotes/gnta-stock-quote/">GNTA</a>) stock in relation to its safety as an investment overall. Readers have noticed that multiple recommendations above have only one analyst rating. I don&rsquo;t have to explain why that introduces a lot of risk overall. The thing I want to note about Genenta Science is that it has <a href="https://stockanalysis.com/stocks/gnta/forecast/">two target prices,</a> one at $15 and the other at $25. Thus, the consensus price is $20. Genenta Science shares trade at $3.30.



While the company is attractive for its raw return potential, I should also note that there are a lot of unknowns with this company. It is an Italian company and doesn&rsquo;t provide a lot in the way of information. It&rsquo;s a lot easier to find updates on domestic companies. The information we do have is a<a href="https://ir.genenta.com/static-files/db77523d-9bdf-47bd-8120-02eb11e0d7df"> financial report dating from the end of 2023.</a> It simply shows the company is not producing much in the way of revenues.



The stock offers so much potential because the company is developing a stem cell platform for the safe treatment of solid tumors. It has <a href="https://www.globenewswire.com/news-release/2024/02/08/2825783/0/en/Genenta-Demonstrated-Reprogramming-of-the-Tumor-Microenvironment-in-GBM-Patients-Paving-the-Way-for-Innovative-Treatments-of-Solid-Tumors.html">demonstrated the potential</a> to reprogram the cells of glioblastoma patients.&nbsp;



<h2>Affimed (AFMD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/red-blood-cells-300x169.jpg" alt="3d rendering red blood cells in vein"><div>Source: Phonlamai Photo / Shutterstock.com</div></div>Affimed (NASDAQ:<a href="https://investorplace.com/stock-quotes/afmd-stock-quote/">AFMD</a>) continues to develop therapeutics for the treatment of lymphoma, a grouping of blood cancers that originate in the lymphatic system.



The stock is interesting for a number of reasons both operational and developmental. The company reduced <a href="https://www.globenewswire.com/news-release/2024/03/28/2853795/0/en/Affimed-Reports-2023-Financial-Results-and-Operational-Progress.html">its workforce by 50% in 2023</a> in an effort to streamline operations.



AFMD is redirecting its resources to three lead candidate programs following the restructuring. That leads me to my next point: The company is doing well from a developmental perspective. Each of those three candidate programs progressed in 2023. Affimed awaits further data readouts from those programs in Q2 and expects dose escalation. That implies current safety and will be used to establish the upper tolerability for those respective programs.&nbsp;



As with any penny biotech stock, failure is a distinct possibility. However, Affimed is well regarded and benefits from a <a href="https://stockanalysis.com/stocks/afmd/forecast/">consensus target price of $32.</a> It currently trades for just over $4.&nbsp;



<h2>Lipocine (LPCN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600d-300x169.jpg" alt="Image of two scientists in lab coats studying results in a lab. best biotech stocks to buy"><div>Source: Shutterstock</div></div>Lipocine (NASDAQ:<a href="https://investorplace.com/stock-quotes/lpcn-stock-quote/">LPCN</a>) stock trades for $6.89 but is expected to rise to $33. Like so many other stocks on this list, Lipocine only has coverage from one analyst. That introduces risk to what is already a risky biotech stock. However, that&rsquo;s the game investors must be willing to play in the risk-fueled world of pharma stock&nbsp;investing.



As you may have guessed by the firm&rsquo;s name, Lipocine does work in the obesity management space. Candidate drug Lpcn2401 is currently in Phase 2 studies and is showing promise in reducing obesity in patients with at least one co-related morbidity.



However, the company is also developing treatments outside of the weight loss realm. Those programs span disease areas, including postpartum depression, cirrhosis, essential tremors and testosterone replacement therapy.&nbsp;



What&rsquo;s particularly good about the company is that it actually produced positive net income in the most recent quarter. Lipocine <a href="https://www.prnewswire.com/news-releases/lipocine-announces-financial-results-for-the-first-quarter-ended-march-31-2024-302140431.html">reported $3.5 million in net income</a> in the first quarter, reversing a $3.9 million net loss 12 months prior.



On <a href="https://investorplace.com/stock-types/penny-stocks/">Penny Stocks</a> and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More: <a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/">Penny Stocks &mdash; How to Profit Without Getting Scammed</a>



On the date of publication, Alex Sirois did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"> Publishing Guidelines.</a>
<div>Alex Sirois is a freelance contributor to InvestorPlace whose personal stock investing style is focused on long-term, buy-and-hold, wealth-building stock picks. Having worked in several industries from e-commerce to translation to education and utilizing his MBA from George Washington University, he brings a diverse set of skills through which he filters his writing.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/05/7-penny-biotech-stocks-to-triple-your-investment/">7 Penny Biotech Stocks to Triple Your Investment</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 Penny Biotech Stocks to Triple Your Investment

Maxim Group analyst Jason McCarthy maintained a Buy rating on Genenta Science SpA Sponsored ADR (GNTA – Research Report) yesterday and set a price ...

Buy Rating Affirmed for Genenta Science Amid Promising Developments in Gene Therapy Trials

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Danaher (DHR – Research Report) and Genenta Science SpA Sponsored...

Analysts Offer Insights on Healthcare Companies: Danaher (DHR) and Genenta Science SpA Sponsored ADR (GNTA)

09:35 EDT Genenta Science (GNTA) SPA (ADR) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking fi...

Genenta Science SPA (ADR) trading resumes

Genenta Science (GNTA) announced that Pierluigi Paracchi, CEO, will attend as a speaker to the Italy-U.S. meeting "Cross-Border Investments and Str...

Genenta Science CEO to present at U.S. Senate meeting

AFMD

ANIX

CING

FGEN

GNTA

LPCN

NVCT

RLMD

Press Releases

General

Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

Management

Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer

Genenta's CEO to present at the U.S. Senate meeting on "Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective"

Comments

Genenta Science

Notizie

Ultime notizie per Genenta Science (NASDAQ:GNTA) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO